Equine Oncology: Common Tumors and Treatment

Veterinarians and horse owners managing equine neoplasia require accurate diagnostic information and practical treatment guidance for the most common tumor types encountered in equine practice. This article covers sarcoids, squamous cell carcinoma, melanoma, lymphoma, and mast cell tumors, with emphasis on diagnostic methods including biopsy, cytology, and imaging, along with treatment options such as surgery, cryotherapy, chemotherapy, and immunotherapy. The content is based on peer-reviewed veterinary literature and official veterinary resources to support clinical decision-making and owner education.

At a Glance

Sarcoids

Sarcoids are the most common cutaneous neoplasm in horses, accounting for a significant proportion of equine skin tumors. They are locally invasive but do not metastasize. Sarcoids are associated with bovine papillomavirus (BPV) infection, and their behavior varies from benign, slow-growing lesions to aggressive, rapidly expanding masses. The range of treatment options reflects the difficulty of achieving consistent results with any single approach, as described in the veterinary literature on equine sarcoid treatment options [6].

Clinical Presentation and Classification

Sarcoids present in several clinical forms. Occult sarcoids appear as areas of alopecia and mild skin thickening, often with a grayish or scaly surface. Verrucous sarcoids have a wart-like, hyperkeratotic appearance. Nodular sarcoids are firm, subcutaneous nodules with intact overlying skin. Fibroblastic sarcoids are fleshy, ulcerated, and rapidly growing masses that resemble granulation tissue. Mixed sarcoids combine features of multiple types. Malevolent sarcoids are highly aggressive, locally invasive, and may track along lymphatic vessels.

Common locations include the head, neck, limbs, ventral abdomen, and groin. Sarcoids can occur at sites of previous trauma, including wounds and surgical incisions. Horses with multiple sarcoids may develop new lesions over time, and the number of tumors can increase with age.

Diagnostic Methods

Diagnosis of sarcoid is based on clinical appearance and confirmed by biopsy with histopathology. Biopsy should be performed carefully because sarcoids can become more aggressive after incomplete excision or trauma. Incisional biopsy is preferred for large or suspicious lesions. Excisional biopsy may be appropriate for small, well-defined masses.

Polymerase chain reaction (PCR) testing for BPV DNA can support the diagnosis, particularly in atypical cases. Cytology from fine-needle aspirates is less reliable for sarcoid diagnosis because the samples often lack diagnostic cellularity.

Treatment Options

Treatment selection depends on tumor size, location, number, clinical type, and available resources. No single treatment is universally effective, and recurrence is possible. The systematic review of equine sarcoid treatments highlights the range of available options and the importance of matching treatment to tumor characteristics [8].

Surgical excision is a common treatment for sarcoids. Wide surgical margins are recommended because sarcoids extend microscopically beyond visible tumor borders. Incomplete excision is associated with recurrence and may lead to more aggressive tumor behavior. For small, well-defined sarcoids, complete excision with 1 to 2 cm margins is often attempted.

Cryotherapy involves freezing the tumor tissue with liquid nitrogen. This technique is suitable for small, well-defined sarcoids, particularly verrucous and nodular types. Multiple freeze-thaw cycles are typically required. Cryotherapy may be combined with surgical debulking for larger lesions.

Immunotherapy with bacillus Calmette-Guerin (BCG) vaccine has been used for sarcoid treatment. BCG immunotherapy mechanisms and clinical efficacy in equine sarcoid treatment have been described in the veterinary oncology literature [7]. This approach is most effective for periocular sarcoids and small nodular lesions. Multiple injections are usually required at intervals of several weeks.

Topical therapies include various agents applied directly to the tumor. Topical betulinic acid has been investigated for treatment of equine sarcoid [11]. Other topical treatments include imiquimod, acyclovir, and 5-fluorouracil, though evidence for their efficacy varies. Topical treatments require consistent application over weeks to months.

Radiation therapy is effective for sarcoids, particularly those in locations where surgical excision is difficult, such as the periocular region. Brachytherapy and teletherapy are available at specialized centers. Radiation therapy may require multiple sessions and general anesthesia.

Treatment Selection Considerations

For small, solitary sarcoids, surgical excision or cryotherapy may be appropriate. For periocular sarcoids, BCG immunotherapy or radiation therapy are often preferred. For multiple or recurrent sarcoids, a combination of treatments may be necessary. Owner compliance with repeated treatments and follow-up visits affects outcomes.

The historical perspective on equine sarcoid treatment notes that optimism about treatment outcomes has increased over time, though challenges remain [10]. Treatment selection should consider the horse's age, use, and value, as well as the owner's financial resources and commitment to follow-up care.

Prognosis

Prognosis varies by tumor type and treatment. Occult and verrucous sarcoids have a better prognosis than fibroblastic and malevolent types. Complete surgical excision with clean margins offers the best chance of cure. Recurrence is common after incomplete treatment, and recurrent sarcoids may be more aggressive. Long-term monitoring is recommended because new sarcoids can develop at other sites.

Squamous Cell Carcinoma

Squamous cell carcinoma (SCC) is the second most common equine neoplasm and the most common malignant tumor of the eye and external genitalia. SCC arises from squamous epithelial cells and can be locally invasive with potential for metastasis.

Clinical Presentation

SCC occurs most frequently in non-pigmented skin and mucous membranes exposed to ultraviolet radiation. Common locations include the third eyelid, cornea, conjunctiva, eyelids, external genitalia (penis, prepuce, vulva), and perianal region. Ocular SCC typically appears as a raised, pink, ulcerated mass on the third eyelid or limbus. Genital SCC presents as a proliferative or ulcerative lesion on the penis or vulva.

Horses with non-pigmented periocular skin and those living in high-altitude or sunny environments are at increased risk. Draft breeds and Appaloosas may have higher incidence. Geldings and stallions are at higher risk for genital SCC.

Diagnostic Methods

Diagnosis is confirmed by biopsy with histopathology. Incisional biopsy of a representative portion of the mass is recommended. Cytology from impression smears or fine-needle aspirates can provide supportive evidence but is not definitive.

Imaging may be indicated to assess local invasion and regional lymph node involvement. Ultrasonography, radiography, and computed tomography can help determine tumor extent. Regional lymph node aspiration should be performed to evaluate for metastasis.

Treatment Options

Surgical excision is the primary treatment for SCC. Wide surgical margins are essential. For ocular SCC, surgical options include keratectomy, third eyelid excision, and enucleation for advanced cases. For genital SCC, partial phallectomy or vulvectomy may be necessary. Complete excision with clean margins offers the best prognosis.

Cryotherapy can be used for small, superficial SCC lesions, particularly on the eyelids and external genitalia. Multiple freeze-thaw cycles are required. Cryotherapy is less effective for large or invasive tumors.

Radiation therapy is effective for ocular and periocular SCC. Strontium-90 plesiotherapy is commonly used for superficial corneal and conjunctival lesions. Brachytherapy with iridium-192 or other isotopes is used for larger tumors. Radiation therapy requires specialized equipment and multiple treatments.

Topical chemotherapy with 5-fluorouracil or mitomycin C has been used for superficial ocular SCC. These agents require repeated application and careful handling. Protective gloves should be worn during application.

Prognosis

Prognosis depends on tumor size, location, and completeness of excision. Small, superficial SCC treated with complete surgical excision has a good prognosis. Advanced or recurrent SCC has a guarded prognosis. Metastasis to regional lymph nodes and distant sites can occur, particularly with genital SCC. Regular monitoring for recurrence and metastasis is essential.

Melanoma

Melanoma is a common neoplasm in horses, particularly in gray horses. Most equine melanomas are benign, but malignant forms occur. Melanomas arise from melanocytes and can be cutaneous, ocular, or oral.

Clinical Presentation

Cutaneous melanoma is most common in gray horses, with incidence increasing with age. Typical locations include the perineum, tail, lips, eyelids, and external genitalia. Lesions appear as darkly pigmented nodules or masses that may be solitary or multiple. Oral melanomas occur on the gums, tongue, and palate. Ocular melanomas involve the uveal tract, including the iris and choroid.

Benign melanomas grow slowly and remain localized. Malignant melanomas grow rapidly, invade locally, and can metastasize to regional lymph nodes and internal organs. Horses with multiple melanomas may develop hundreds of lesions over time.

Diagnostic Methods

Diagnosis is based on clinical appearance and confirmed by biopsy with histopathology. Fine-needle aspiration cytology can be diagnostic for pigmented lesions. Immunohistochemistry for melanocytic markers may be needed for amelanotic (non-pigmented) melanomas.

Treatment Options

Surgical excision is the treatment of choice for solitary, accessible melanomas. Wide surgical margins are recommended. For multiple or diffuse melanomas, complete surgical excision may not be possible. Surgical removal of large or problematic melanomas can improve quality of life.

Cryotherapy can be used for small, superficial melanomas. This technique is less effective for large or deeply invasive tumors. Multiple freeze-thaw cycles are required.

Immunotherapy with cimetidine has been used for equine melanoma, though evidence for efficacy is limited. Other immunomodulatory approaches are under investigation.

Topical therapies including betulinic acid have been studied for equine melanoma treatment [11]. These treatments require consistent application and may take months to show effect.

Prognosis

Prognosis for benign melanomas is good with complete surgical excision. Malignant melanomas have a guarded prognosis due to potential for metastasis. Horses with multiple or rapidly growing melanomas should be monitored closely. Internal metastasis can occur without obvious external changes.

Lymphoma

Lymphoma is a malignant neoplasm of lymphoid tissue that can affect multiple organ systems in horses. It is the most common hematopoietic tumor in horses and can present in various forms.

Clinical Presentation

Lymphoma in horses can be classified by anatomic distribution. Multicentric lymphoma involves multiple lymph nodes and organs. Alimentary lymphoma affects the gastrointestinal tract. Mediastinal lymphoma involves the thymus and thoracic lymph nodes. Cutaneous lymphoma presents as skin nodules or plaques. Central nervous system lymphoma has been reported in horses, including cases with neurolymphomatosis and lymphoproliferative disease affecting the central nervous system [12][13].

Clinical signs vary by location. Peripheral lymphadenopathy is common in multicentric lymphoma. Weight loss, lethargy, fever, and anorexia are frequent systemic signs. Alimentary lymphoma causes colic, diarrhea, and weight loss. Mediastinal lymphoma may cause respiratory distress and pleural effusion. Neurologic signs occur with central nervous system involvement [15].

Diagnostic Methods

Diagnosis requires biopsy of affected tissue with histopathology and immunohistochemistry. Lymph node aspiration cytology can provide supportive evidence but may not be definitive. Imaging including ultrasonography and radiography helps assess internal organ involvement.

Complete blood count and serum biochemistry may show abnormalities including anemia, thrombocytopenia, hyperglobulinemia, and elevated liver enzymes. Bone marrow aspiration may be indicated in some cases.

Treatment Options

Chemotherapy is the primary treatment for equine lymphoma. Various protocols using drugs such as doxorubicin, cyclophosphamide, vincristine, and prednisolone have been described. Treatment is typically palliative instead of curative. Response to chemotherapy varies between individuals.

Supportive care including nutritional support, fluid therapy, and management of secondary infections is important. Corticosteroids may provide temporary improvement in clinical signs.

Prognosis

Prognosis for equine lymphoma is guarded. Response to chemotherapy varies, and most horses eventually relapse. Median survival times are limited, though some horses achieve remission. Factors affecting prognosis include tumor type, stage at diagnosis, and response to initial treatment.

Mast Cell Tumors

Mast cell tumors are uncommon in horses compared to other species. They arise from mast cells and are typically benign in horses, though malignant forms occur.

Clinical Presentation

Equine mast cell tumors present as solitary or multiple cutaneous nodules. Common locations include the head, neck, trunk, and limbs. Lesions are firm, well-circumscribed, and may be pruritic or ulcerated. Some mast cell tumors are associated with collagenolysis and appear as soft, fluctuant masses.

Diagnostic Methods

Diagnosis is confirmed by biopsy with histopathology. Fine-needle aspiration cytology shows characteristic mast cells with metachromatic granules. Special stains including toluidine blue and Giemsa highlight mast cell granules.

Treatment Options

Surgical excision is the treatment of choice for solitary mast cell tumors. Complete excision is usually curative. Wide surgical margins are recommended to ensure complete removal.

Cryotherapy can be used for small, superficial lesions. Multiple freeze-thaw cycles are required.

Prognosis

Prognosis for equine mast cell tumors is excellent with complete surgical excision. Recurrence is uncommon. Malignant mast cell tumors with metastasis are rare. Horses with multiple mast cell tumors should be monitored for development of new lesions.

Diagnostic Methods

Accurate diagnosis is essential for appropriate treatment planning. The following diagnostic methods are used in equine oncology.

Biopsy

Biopsy is the gold standard for diagnosis of equine neoplasia. Incisional biopsy involves removal of a representative portion of the mass. Excisional biopsy involves complete removal of the mass. Biopsy specimens should be submitted in 10% neutral buffered formalin for histopathology. Multiple samples may be needed for large or heterogeneous tumors.

Cytology

Cytology from fine-needle aspirates or impression smears can provide rapid preliminary diagnosis. Cytology is most useful for round cell tumors including lymphoma and mast cell tumors. Epithelial and mesenchymal tumors may be more difficult to classify cytologically. Cytology should be interpreted in conjunction with clinical findings.

Imaging

Imaging helps assess tumor extent, local invasion, and metastasis. Ultrasonography is useful for evaluating internal organs and lymph nodes. Radiography is used for thoracic and skeletal lesions. Computed tomography and magnetic resonance imaging provide detailed anatomic information for surgical planning. Nuclear scintigraphy may be useful for detecting bone involvement.

Treatment Options

Treatment selection depends on tumor type, location, size, number, and clinical behavior. The following treatment modalities are available for equine neoplasia.

Surgical Excision

Surgical excision is the most common treatment for equine tumors. Wide surgical margins are recommended for malignant tumors. Incomplete excision is associated with recurrence. Surgical planning should consider tumor location, local anatomy, and available surgical expertise.

Cryotherapy

Cryotherapy involves freezing tumor tissue with liquid nitrogen. This technique is suitable for small, superficial tumors. Multiple freeze-thaw cycles are required for effective tumor destruction. Cryotherapy may be combined with surgical debulking for larger lesions.

Chemotherapy

Chemotherapy is used primarily for lymphoma and other systemic neoplasms. Topical chemotherapy agents are used for superficial tumors including SCC. Systemic chemotherapy requires careful monitoring for adverse effects. Chemotherapy protocols should be designed by veterinarians experienced in medical oncology.

Immunotherapy

Immunotherapy stimulates the immune system to recognize and destroy tumor cells. BCG immunotherapy is used for sarcoid treatment [7]. Other immunomodulatory approaches are under investigation. Immunotherapy may require multiple treatments over several weeks.

Radiation Therapy

Radiation therapy is effective for tumors in locations where surgical excision is difficult. Strontium-90 plesiotherapy is used for superficial ocular tumors. Brachytherapy and teletherapy are available at specialized centers. Radiation therapy requires multiple sessions and may require general anesthesia.

Common Failure Patterns

Treatment failure in equine oncology can result from several factors.

Incomplete Excision

Incomplete surgical excision is a common cause of recurrence. Tumors extend microscopically beyond visible borders, and inadequate margins lead to residual disease. Intraoperative assessment of margins is difficult for many equine tumors.

Tumor Aggressiveness

Some tumors are inherently aggressive and resistant to treatment. Fibroblastic and malevolent sarcoids, malignant melanomas, and advanced SCC are examples. Tumor behavior may change over time, with initially benign lesions becoming more aggressive.

Metastasis

Metastasis to regional lymph nodes and distant organs limits treatment success. Early detection and treatment of primary tumors reduce metastasis risk. Regular monitoring for metastasis is essential for horses with malignant tumors.

Owner Compliance

Owner compliance with treatment recommendations affects outcomes. Repeated treatments, follow-up visits, and monitoring are essential for success. Financial constraints may limit treatment options. Clear communication about expected outcomes and costs is important.

Professional Escalation Criteria

Veterinarians should refer cases to specialists when appropriate.

When to Refer

Referral to a veterinary oncologist or surgical specialist is indicated for complex cases. Large or invasive tumors, tumors in difficult locations, and tumors requiring radiation therapy or advanced chemotherapy should be referred. Cases with diagnostic uncertainty may benefit from specialist consultation.

Urgent Referral

Urgent referral is indicated for tumors causing functional impairment. Airway obstruction from pharyngeal or laryngeal tumors, vision loss from ocular tumors, and colic from alimentary tumors require immediate attention. Rapidly growing tumors causing pain or discomfort should be evaluated promptly.

Monitoring After Treatment

Regular monitoring after treatment is essential. Horses should be examined for recurrence at the treatment site and for new tumor development. Regional lymph nodes should be palpated. Owners should be educated about signs of recurrence and metastasis. Follow-up examinations should be scheduled at regular intervals based on tumor type and treatment.

Practical Decision Framework for Equine Tumor Management: A Stage-Based Approach

Selecting the appropriate treatment for an equine tumor requires a structured decision process that accounts for tumor biology, horse factors, owner resources, and available expertise. A stage-based decision framework helps veterinarians and owners move from diagnosis through treatment selection to monitoring in a logical sequence. This framework is designed to reduce common failure patterns including incomplete excision, inappropriate treatment selection, and poor owner compliance.

Stage 1: Diagnostic Confirmation and Characterization

Before any treatment decision, the tumor must be accurately diagnosed and characterized. This stage involves three components: histopathologic diagnosis, clinical staging, and biologic behavior assessment.

Histopathologic diagnosis requires biopsy with interpretation by a veterinary pathologist. The biopsy method matters. Incisional biopsy is appropriate for large tumors, tumors in cosmetically sensitive areas, and tumors where the diagnosis is uncertain. Excisional biopsy is appropriate for small tumors where complete removal with margins is feasible. The biopsy report should include tumor type, histologic grade if applicable, mitotic index, and margin assessment if an excisional biopsy was performed.

Clinical staging determines the extent of disease. For cutaneous tumors, staging includes measurement of the primary tumor in three dimensions, assessment of regional lymph nodes by palpation and aspiration cytology, and evaluation for distant metastasis. For suspected lymphoma, staging includes complete blood count, serum biochemistry, abdominal ultrasonography, thoracic radiography, and biopsy of affected lymph nodes or organs. The Merck Veterinary Manual provides guidance on diagnostic approaches for equine neoplasia [4].

Biologic behavior assessment considers the tumor's known natural history. Sarcoids are locally invasive but do not metastasize. Squamous cell carcinoma can be locally invasive and may metastasize to regional lymph nodes. Melanoma in gray horses is often benign but can become malignant. Lymphoma is a systemic disease. Mast cell tumors are typically benign in horses. This assessment guides treatment aggressiveness and monitoring frequency.

Stage 2: Treatment Selection Based on Tumor and Horse Factors

Once the tumor is characterized, treatment selection proceeds through a systematic evaluation of tumor factors, horse factors, and owner factors.

Tumor factors include size, location, number of lesions, clinical type, and prior treatment history. Small tumors less than 2 cm in diameter are generally amenable to local treatments including surgical excision or cryotherapy. Large tumors may require debulking followed by adjunctive therapy. Location affects treatment options. Periocular tumors may be treated with BCG immunotherapy or radiation therapy instead of surgery. Tumors on the limbs may have limited surgical margins. Multiple tumors may require staged treatments or combination therapy. Prior treatment failure narrows options and may indicate the need for referral.

Horse factors include age, use, value, and overall health. Older horses may not be candidates for aggressive treatment. Performance horses require treatments that allow return to function. Breeding horses require treatments that preserve fertility. Horses with concurrent disease may have increased anesthetic risk. The horse's temperament affects the feasibility of repeated treatments.

Owner factors include financial resources, time commitment, geographic access to specialized care, and treatment goals. Owners should understand that some treatments require multiple visits over weeks to months. Financial constraints may limit options. Clear communication about expected costs, success rates, and potential complications is essential before treatment begins.

Stage 3: Treatment Implementation and Monitoring

Treatment implementation follows a planned protocol with defined endpoints. Monitoring occurs at scheduled intervals to detect recurrence, metastasis, or new tumor development.

Treatment protocols should specify the treatment modality, number of sessions, interval between sessions, and criteria for treatment modification or discontinuation. For surgical excision, the protocol includes planned margins, intraoperative assessment, and postoperative care. For cryotherapy, the protocol includes number of freeze-thaw cycles, target tissue temperature, and post-treatment wound management. For immunotherapy, the protocol includes dose, injection technique, and treatment interval.

Monitoring schedule depends on tumor type and treatment. For completely excised benign tumors, re-examination at 3, 6, and 12 months is reasonable. For malignant tumors or incompletely excised tumors, re-examination at 1, 3, 6, and 12 months is recommended. Monitoring includes physical examination of the treatment site, palpation of regional lymph nodes, and imaging as indicated. Owners should be educated to monitor for signs of recurrence including new masses, ulceration, bleeding, or changes in behavior.

Treatment modification may be necessary based on response. Tumors that do not respond to initial treatment may require alternative therapy. Tumors that recur after treatment may require more aggressive intervention. Progressive disease despite treatment warrants referral to a specialist.

Stage 4: Long-Term Surveillance and Management

Equine tumors can recur months to years after treatment. Long-term surveillance is essential for early detection of recurrence and new tumor development.

Surveillance frequency decreases over time but never stops. For horses with a history of sarcoid, annual skin examination is recommended. For horses with a history of melanoma, semi-annual examination is recommended because new lesions can develop. For horses with a history of squamous cell carcinoma, examination every 6 months for the first 2 years, then annually, is appropriate.

Owner education about tumor recognition is important. Owners should be shown what to look for including changes in skin color, texture, or contour, new lumps or bumps, non-healing sores, and changes in existing tumors. Photographs of the treatment site help owners recognize changes.

Record keeping supports long-term management. A tumor log should include date of diagnosis, tumor type, location, size, treatment date and method, histopathology results, and follow-up findings. This record helps track tumor behavior over time and guides future treatment decisions.

Records and Measurements

Accurate records support clinical decision-making and outcome assessment. The following measurements should be documented for each tumor.

Tumor dimensions should be measured in three planes using calipers. Length, width, and height are recorded in millimeters or centimeters. Photographs with a scale marker provide visual documentation. For multiple tumors, a body map showing tumor locations is helpful.

Treatment parameters should be recorded for each treatment session. For surgery, record incision length, margin width, closure method, and intraoperative findings. For cryotherapy, record number of freeze-thaw cycles, freeze time, thaw time, and tissue temperature if measured. For immunotherapy, record dose, injection volume, number of injection sites, and any adverse reactions.

Outcome assessment uses standardized terminology. Complete response means no visible tumor. Partial response means tumor size reduction of 50% or more. Stable disease means tumor size change less than 50% reduction or 25% increase. Progressive disease means tumor size increase of 25% or more or development of new lesions. Recurrence means tumor regrowth at the treatment site after complete response.

Complication recording documents adverse events. Complications include wound dehiscence, infection, hemorrhage, tumor seeding, and treatment-related toxicity. Severity is graded as mild (self-limiting), moderate (requires treatment), or severe (life-threatening or requires hospitalization).

Common Failure Patterns

Understanding why treatments fail helps veterinarians and owners make informed decisions and avoid predictable problems.

Incomplete excision is the most common cause of local recurrence. Tumors extend microscopically beyond visible borders. Sarcoids in particular have microscopic extensions that are not apparent during surgery. The systematic review of equine sarcoid treatments notes that incomplete excision is associated with recurrence and may lead to more aggressive tumor behavior [8]. Wide surgical margins of at least 1 cm for small tumors and 2 cm for larger tumors are recommended. Intraoperative assessment of margins is difficult, and postoperative histopathologic margin assessment is essential.

Inappropriate treatment selection occurs when the treatment does not match the tumor biology. Treating a fibroblastic sarcoid with cryotherapy alone is unlikely to succeed because the tumor is too large and invasive. Treating a malignant melanoma with topical therapy alone is unlikely to control the disease. Treatment selection should be based on tumor type, size, location, and clinical behavior.

Inadequate treatment intensity results from using too few treatment sessions, too low a dose, or too short a treatment duration. BCG immunotherapy requires multiple injections at 2 to 4 week intervals. Cryotherapy requires multiple freeze-thaw cycles. Topical treatments require consistent application for weeks to months. Owners must understand the treatment protocol and commit to completing it.

Owner non-compliance is a common cause of treatment failure. Owners may miss follow-up appointments, discontinue treatments prematurely, or fail to monitor for recurrence. Clear communication about the treatment plan, expected outcomes, and consequences of non-compliance is essential. Written instructions and scheduled reminders improve compliance.

Tumor progression during treatment indicates that the tumor is resistant to the chosen therapy. Rapidly growing tumors may outpace treatment. In these cases, alternative therapy or referral should be considered promptly. Waiting too long to change treatment allows the tumor to become more advanced.

Professional Escalation Criteria

Veterinarians should recognize when a case exceeds their expertise or available resources and refer to a specialist.

Referral to a veterinary oncologist is indicated for lymphoma requiring chemotherapy, tumors that have failed initial treatment, and tumors where radiation therapy is the best option. The American College of Veterinary Internal Medicine provides a directory of board-certified veterinary oncologists [3].

Referral to a surgical specialist is indicated for tumors in difficult locations including the periocular region, oral cavity, and urogenital tract. Large tumors requiring advanced surgical techniques such as flap reconstruction should be referred. Tumors involving critical structures such as the eye, airway, or major blood vessels require specialist expertise.

Referral for radiation therapy is indicated for periocular sarcoid, ocular squamous cell carcinoma, and tumors in locations where surgical excision would cause functional impairment. Radiation therapy is available at veterinary teaching hospitals and specialized referral centers.

Urgent referral is indicated for tumors causing functional impairment. Airway obstruction from pharyngeal or laryngeal tumors requires immediate attention. Vision loss from ocular tumors requires prompt evaluation. Colic from alimentary lymphoma requires emergency assessment. Rapidly growing tumors causing pain or discomfort should be evaluated without delay.

Welfare and Safety Context

Equine tumor management must consider animal welfare throughout the treatment process. Pain assessment, quality of life evaluation, and humane endpoints are essential components of responsible care.

Pain assessment should be performed before, during, and after treatment. Pain scales validated for horses include behavioral observation, facial expression scoring, and physiologic parameters. Tumors can cause pain through direct invasion, ulceration, infection, or compression of adjacent structures. Treatment procedures including surgery and cryotherapy cause acute pain that requires appropriate analgesia.

Quality of life assessment considers the horse's ability to eat, drink, move comfortably, interact with herdmates, and perform its intended use. Owners should be asked about changes in behavior, appetite, and activity level. A quality of life scoring system helps objectify these assessments.

Humane endpoints should be established before treatment begins. For tumors that cannot be controlled, euthanasia may be the most humane option. Criteria for euthanasia include uncontrolled pain, inability to eat or drink, respiratory distress, and progressive debilitation. The World Organisation for Animal Health provides guidance on animal welfare and euthanasia [5].

Treatment-related welfare concerns include pain from procedures, side effects from medications, and stress from repeated handling. Analgesia should be provided for all surgical procedures. Non-steroidal anti-inflammatory drugs are commonly used for postoperative pain. Local anesthesia can reduce pain during cryotherapy and minor surgical procedures. Sedation reduces stress during repeated treatments.

Implementation Checklist

The following checklist helps veterinarians implement the stage-based decision framework in clinical practice.

Before treatment:

• Confirm histopathologic diagnosis
• Complete clinical staging
• Assess tumor biologic behavior
• Evaluate horse factors including age, use, and health status
• Discuss treatment options with owner including expected outcomes, costs, and complications
• Establish treatment goals and endpoints
• Document tumor measurements and photographs
• Obtain informed consent

During treatment:

• Follow planned treatment protocol
• Document treatment parameters
• Monitor for complications
• Provide appropriate analgesia
• Assess response at each treatment session
• Modify treatment if indicated

After treatment:

• Schedule follow-up examinations
• Educate owner about monitoring
• Provide written instructions
• Document outcomes
• Report results to referring veterinarian if applicable

Long-term:

• Maintain tumor log
• Schedule surveillance examinations
• Monitor for new tumor development
• Reassess treatment goals if recurrence occurs
• Consider referral for complex cases

This stage-based decision framework provides a structured approach to equine tumor management that reduces common failure patterns and improves outcomes. By systematically working through diagnostic confirmation, treatment selection, implementation, and long-term surveillance, veterinarians and owners can make informed decisions that match the tumor biology, horse factors, and available resources.

Frequently Asked Questions

What is the most common tumor in horses?

Sarcoid is the most common cutaneous neoplasm in horses. It is associated with bovine papillomavirus infection and can present in several clinical forms including occult, verrucous, nodular, fibroblastic, and mixed types. Sarcoids are locally invasive but do not metastasize.

How are equine sarcoids diagnosed?

Sarcoids are diagnosed based on clinical appearance and confirmed by biopsy with histopathology. PCR testing for BPV DNA can support the diagnosis. Biopsy should be performed carefully because sarcoids can become more aggressive after incomplete excision or trauma. Cytology from fine-needle aspirates is less reliable for sarcoid diagnosis.

What treatment options are available for equine sarcoids?

Treatment options include surgical excision, cryotherapy, immunotherapy with BCG, topical therapies, and radiation therapy. Treatment selection depends on tumor size, location, clinical type, and number of lesions. No single treatment is universally effective. Recurrence is possible after any treatment.

Can equine melanoma be cured?

Benign melanomas can be cured with complete surgical excision. Malignant melanomas have a guarded prognosis due to potential for metastasis. Gray horses are at increased risk for melanoma development. Horses with multiple melanomas may develop new lesions over time.

What are the signs of lymphoma in horses?

Signs of lymphoma vary by location. Peripheral lymphadenopathy, weight loss, lethargy, fever, and anorexia are common. Alimentary lymphoma causes colic and diarrhea. Mediastinal lymphoma causes respiratory distress. Central nervous system lymphoma causes neurologic signs. Diagnosis requires biopsy with histopathology.

How is equine lymphoma treated?

Chemotherapy is the primary treatment for equine lymphoma. Various protocols using drugs such as doxorubicin, cyclophosphamide, vincristine, and prednisolone have been described. Treatment is typically palliative instead of curative. Supportive care including nutritional support and fluid therapy is important.

What is the prognosis for horses with squamous cell carcinoma?

Prognosis depends on tumor size, location, and completeness of excision. Small, superficial SCC treated with complete surgical excision has a good prognosis. Advanced or recurrent SCC has a guarded prognosis. Metastasis can occur, particularly with genital SCC. Regular monitoring for recurrence is essential.

When should a horse with a tumor be referred to a specialist?

Referral to a veterinary oncologist or surgical specialist is indicated for large or invasive tumors, tumors in difficult locations, and tumors requiring radiation therapy or advanced chemotherapy. Urgent referral is indicated for tumors causing functional impairment such as airway obstruction or vision loss. Cases with diagnostic uncertainty may benefit from specialist consultation.

Related Veterinary Guides

• Diagnostic Medical Sonography Programs
• Veterinary Clinical Methods Procedures Surgical Interventions
• Swine Respiratory Disease Observation And Diagnostics
• Ihc And Ifa Tissue Diagnostics
• Working Equid Dental Care Routine Problem Management

References and Further Reading

• aaep.org
• www.merckvetmanual.com
• www.acvim.org
• Merck Veterinary Manual. Merck Veterinary Manual.
• Animal Health and Welfare. World Organisation for Animal Health.
• The Equine Sarcoid: Why Are There so Many Treatment Options?. The Veterinary clinics of North America. Equine practice, 2019.
• BCG Immunotherapy in Equine Sarcoid Treatment: Mechanisms, Clinical Efficacy, and Challenges in Veterinary Oncology.. Viruses, 2025.
• Treatment of equine sarcoids: A systematic review.. Equine veterinary journal, 2024.
• Neoplasia.. The Veterinary clinics of North America. Equine practice, 1993.
• Equine sarcoid--time for optimism.. Equine veterinary journal, 1985.
• Topical betulinic acid for treatment of equine melanoma and sarcoid.. Frontiers in veterinary science, 2026.
• Neurolymphomatosis in Three Horses with Multicentric T-cell-rich B-cell Lymphoma. Journal of Comparative Pathology, 2014.
• Lymphoproliferative Disease with Features of Lymphoma in the Central Nervous System of a Horse. Journal of Comparative Pathology, 2008.
• Multicentric lymphoma in a Brazilian Warmblood Horse - Case report. Revista Brasileira De Medicina Veterinaria, 2016.
• Lymphoma of the Central Nervous System in Horses. Compendium on Continuing Education for the Practicing Veterinarian, 2001.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.